Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study the Feasibility of Permanent Use of inControl for the Treatment of Type 1 Diabetes (IDCLTraining)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02892604
Recruitment Status : Terminated (not enough participants)
First Posted : September 8, 2016
Last Update Posted : May 4, 2020
Sponsor:
Collaborators:
MEDBIOMED, Montpellier, France
Jaeb Center for Health Research
University of Virginia
Information provided by (Responsible Party):
University Hospital, Montpellier

Brief Summary:
A new version of the DiAs artificial pancreas (AP) system has been developed in view of wide scale outpatient trials. Denominated as inControl , it includes improved user interface and communication modules while closed-loop algorithms remain similar. During this pilot study, the investigators will evaluate this new version of AP for a two-week period during which the patients will use it for closed-loop insulin delivery 24/7 The main goal is train the clinical team with the new system and collect patient opinions on system acceptance from questionnaires. If this trial is conclusive, a randomized 6-month multicentre study including 240 patients will be initiated. A total of 5 patients will be included in this training study over a 4-week period.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Device: insulin pump to inControl AP platform Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Evaluation Study of the Feasibility of a Permanent Use in Free-life of inControl Artificial Pancreas System for the Treatment of Type 1 Diabetes
Actual Study Start Date : November 25, 2016
Actual Primary Completion Date : November 28, 2016
Actual Study Completion Date : December 16, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: insulin delivery driven by inControl

Closed-loop insulin delivery using inControl AP system is assessed for two weeks, 24/7.

Connection of continuous glucose monitoring (CGM) system and insulin pump to inControl AP platform, all wireless and wearable, in free-life conditions Insulin from the pump is delivered according to the closed-loop algorithm fed by CGM data.

Device: insulin pump to inControl AP platform
Insulin from the pump is delivered according to the closed-loop algorithm fed by CGM data.




Primary Outcome Measures :
  1. Percent time of active insulin closed-loop delivery [ Time Frame: 2 weeks ]
    Percent time while AP system is active permanently


Secondary Outcome Measures :
  1. Percent time with blood glucose in target range [ Time Frame: 2 weeks ]
    Percent time while blood glucose is kept in safe 70-180 mg/dl range



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 1 diabetes mellitus since more than one year, treated by insulin since at least one year
  • Treatment by insulin pump since at least 6 months
  • Glycated hemoglobin (HbA1c) below 10.5% at inclusion visit
  • For women of child bearing age, no current pregnancy and use of an efficient contraception during the whole research participation
  • Agreement on no use of drugs or products used for reduction of blood glucose levels, such as metformin or GLP1 analogs, except if this therapy has been used for at least 3 months before study start
  • Agreement on stopping closed-loop insulin delivery after acetaminophen use and 4 following hours
  • Agreement on suspending use of patient CGM device during the study period while study CGM will be used
  • Access to the internet and a mobile phone network at home
  • Agreement on following study procedures
  • Affiliation to the French social security system or a similar healthcare coverage system
  • Mandatory written informed consent

Exclusion Criteria:

  • Need for chronic use of acetaminophen
  • Start of use of drugs or products used for reduction of blood glucose levels, such as metformin or GLP1 analogs during the 3 months before inclusion
  • Hemophilia or other coagulation disorders
  • Psychological and/or cognitive troubles which may impair the appropriate following of study procedures
  • Diabetic ketoacidosis during the last 6 months
  • Acute cardiovascular event during the last 12 months
  • Severe hypoglycaemia with convulsions or loss of conscience during the last 12 months
  • Use of a therapy with significant impact on glucose metabolism
  • Cystic fibrosis
  • Lack of nearby third-party assistance availability in case of troubles
  • Malignant disease, except if considered as cured since at least 10 years
  • Impaired kidney function (serum creatinin > 150 umol/L)
  • Impaired liver status (ALAT or ASAT > 2-times upper normal limit)
  • Active gastroparesis
  • Acute adrenocortical event
  • Alcohol or narcotics abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02892604


Locations
Layout table for location information
France
UHMontpellier
Montpellier, France, 34295
Sponsors and Collaborators
University Hospital, Montpellier
MEDBIOMED, Montpellier, France
Jaeb Center for Health Research
University of Virginia
Investigators
Layout table for investigator information
Study Director: Eric M RENARD, MD, PhD University Hospital, Montpellier
Layout table for additonal information
Responsible Party: University Hospital, Montpellier
ClinicalTrials.gov Identifier: NCT02892604    
Other Study ID Numbers: 9722
First Posted: September 8, 2016    Key Record Dates
Last Update Posted: May 4, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by University Hospital, Montpellier:
Type 1 diabetes
artificial pancreas
closed-loop insulin infusion
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs